Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × BKT140 × Plasma cell × Clear all
NCT01010880 2011-06-10

Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients

Biokine Therapeutics Ltd

Phase 1/2 Completed
16 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡